BRISTOL-MYERS SQUIBB CO (1BMY.MI) Stock Price, Forecast & Analysis
Europe • Euronext Milan • BIT:1BMY • US1101221083
1BMY.MI Key Statistics, Chart & Performance
The current stock price of 1BMY.MI is 45.965 EUR. In the past month the price increased by 4.73%.
1BMY.MI Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to 1BMY.MI.
1BMY.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 1BMY.MI. Both the profitability and the financial health of 1BMY.MI get a neutral evaluation. Nothing too spectacular is happening here.
1BMY.MI Financial Highlights
Over the last trailing twelve months 1BMY.MI reported a non-GAAP Earnings per Share(EPS) of 5.48. The EPS increased by 460.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 12.57% | ||
| ROA | 6.23% | ||
| ROE | 32.55% | ||
| Debt/Equity | 2.41 |
1BMY.MI Forecast & Estimates
34 analysts have analysed 1BMY.MI and the average price target is 48.98 EUR. This implies a price increase of 6.55% is expected in the next year compared to the current price of 45.965.
For the next year, analysts expect an EPS growth of 471.99% and a revenue growth 0.22% for 1BMY.MI
1BMY.MI Ownership
About 1BMY.MI
Company Profile
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Company Info
BRISTOL-MYERS SQUIBB CO
Route 206 And Province Line Road
Princeton NEW JERSEY US
Employees: 34100
Phone: 16092524621
BRISTOL-MYERS SQUIBB CO / 1BMY.MI FAQ
Can you describe the business of BRISTOL-MYERS SQUIBB CO?
Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The company is headquartered in Princeton, New Jersey and currently employs 34,100 full-time employees. The company is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Can you provide the latest stock price for BRISTOL-MYERS SQUIBB CO?
The current stock price of 1BMY.MI is 45.965 EUR. The price decreased by -0.99% in the last trading session.
What is the dividend status of BRISTOL-MYERS SQUIBB CO?
BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a dividend yield of 4.64%. The yearly dividend amount is currently 2.03.
How is the ChartMill rating for BRISTOL-MYERS SQUIBB CO?
1BMY.MI has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the growth outlook for BRISTOL-MYERS SQUIBB CO?
The Revenue of BRISTOL-MYERS SQUIBB CO (1BMY.MI) is expected to grow by 0.22% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of 1BMY stock?
BRISTOL-MYERS SQUIBB CO (1BMY.MI) has a market capitalization of 93.57B EUR. This makes 1BMY.MI a Large Cap stock.
What is the next earnings date for 1BMY stock?
BRISTOL-MYERS SQUIBB CO (1BMY.MI) will report earnings on 2026-02-05, before the market open.